258 related articles for article (PubMed ID: 22983919)
21. ER, PgR, Ki67, p27(Kip1), and histological grade as predictors of pathological complete response in patients with HER2-positive breast cancer receiving neoadjuvant chemotherapy using taxanes followed by fluorouracil, epirubicin, and cyclophosphamide concomitant with trastuzumab.
Kurozumi S; Inoue K; Takei H; Matsumoto H; Kurosumi M; Horiguchi J; Takeyoshi I; Oyama T
BMC Cancer; 2015 Sep; 15():622. PubMed ID: 26345461
[TBL] [Abstract][Full Text] [Related]
22. [Evaluation of two different regimens as neoadjuvant chemotherapy for breast cancer].
Yang D; Tong F; Cao Y; Liu P; Zhou B; Liu H; Qiao X; Zhang J
Zhonghua Zhong Liu Za Zhi; 2002 May; 24(3):303-5. PubMed ID: 12515634
[TBL] [Abstract][Full Text] [Related]
23. A multicenter prospective phase II trial of neoadjuvant epirubicin, cyclophosphamide, and 5-fluorouracil (FEC100) followed by cisplatin-docetaxel with or without trastuzumab in locally advanced breast cancer.
A L-Tweigeri T; AlSayed A; Alawadi S; Ibrahim M; Ashour W; Jaafar H; Abulkhair O; A L-Abdulkarim H; Khalid H; Ajarim D;
Cancer Chemother Pharmacol; 2016 Jan; 77(1):147-53. PubMed ID: 26563257
[TBL] [Abstract][Full Text] [Related]
24. Clinical outcome and predictive factors for docetaxel and epirubicin neoadjuvant chemotherapy of locally advanced breast cancer.
Won HS; Kim YS; Kim JS; Chang ED; Na SJ; Whang IY; Lee DS
Korean J Intern Med; 2020 Nov; 35(6):1489-1496. PubMed ID: 32069523
[TBL] [Abstract][Full Text] [Related]
25. Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center Experience.
Singh JC; Mamtani A; Barrio A; Morrow M; Sugarman S; Jones LW; Yu AF; Argolo D; Smyth LM; Modi S; Schweber S; Boafo C; Patil S; Norton L; Baselga J; Hudis CA; Dang C
Oncologist; 2017 Feb; 22(2):139-143. PubMed ID: 28167568
[TBL] [Abstract][Full Text] [Related]
26. Retrospective study of efficacy and safety of neoadjuvant docetaxel, carboplatin, and trastuzumab in HER2-positive locally advanced and oligometastatic breast cancer: An Indian experience.
Tiwari A; Gogia A; Deo S; Shukla NK; Mathur S; Sharma DN
Indian J Cancer; 2017; 54(1):343-346. PubMed ID: 29199719
[TBL] [Abstract][Full Text] [Related]
27. Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value.
Michlmayr A; Bachleitner-Hofmann T; Baumann S; Marchetti-Deschmann M; Rech-Weichselbraun I; Burghuber C; Pluschnig U; Bartsch R; Graf A; Greil R; Allmaier G; Steger G; Gnant M; Bergmann M; Oehler R
Br J Cancer; 2010 Oct; 103(8):1201-8. PubMed ID: 20877360
[TBL] [Abstract][Full Text] [Related]
28. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.
Untch M; Fasching PA; Konecny GE; Hasmüller S; Lebeau A; Kreienberg R; Camara O; Müller V; du Bois A; Kühn T; Stickeler E; Harbeck N; Höss C; Kahlert S; Beck T; Fett W; Mehta KM; von Minckwitz G; Loibl S
J Clin Oncol; 2011 Sep; 29(25):3351-7. PubMed ID: 21788566
[TBL] [Abstract][Full Text] [Related]
29. High pathologic complete response in HER 2-positive locally advanced breast cancer after primary systemic chemotherapy with weekly docetaxel and epirubicin.
Chen SC; Chang HK; Lin YC; Hsueh S; Cheung YC; Leung WM; Tsai CS; Lo YF; Tsai HP; Shen SC; Chen MF
Jpn J Clin Oncol; 2008 Feb; 38(2):99-105. PubMed ID: 18270380
[TBL] [Abstract][Full Text] [Related]
30. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.
Gianni L; Pienkowski T; Im YH; Tseng LM; Liu MC; Lluch A; Starosławska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi GV; Magazzù D; McNally V; Douthwaite H; Ross G; Valagussa P
Lancet Oncol; 2016 Jun; 17(6):791-800. PubMed ID: 27179402
[TBL] [Abstract][Full Text] [Related]
31. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study.
Untch M; Rezai M; Loibl S; Fasching PA; Huober J; Tesch H; Bauerfeind I; Hilfrich J; Eidtmann H; Gerber B; Hanusch C; Kühn T; du Bois A; Blohmer JU; Thomssen C; Dan Costa S; Jackisch C; Kaufmann M; Mehta K; von Minckwitz G
J Clin Oncol; 2010 Apr; 28(12):2024-31. PubMed ID: 20308670
[TBL] [Abstract][Full Text] [Related]
32. Neoadjuvant triweekly nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for Stage II/III HER2-negative breast cancer: evaluation of efficacy and safety.
Shimada H; Ueda S; Saeki T; Shigekawa T; Takeuchi H; Hirokawa E; Sugitani I; Sugiyama M; Takahashi T; Matsuura K; Yamane T; Kuji I; Hasebe T; Osaki A
Jpn J Clin Oncol; 2015 Jul; 45(7):642-9. PubMed ID: 25989989
[TBL] [Abstract][Full Text] [Related]
33. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.
Iwata H; Sato N; Masuda N; Nakamura S; Yamamoto N; Kuroi K; Kurosumi M; Tsuda H; Akiyama F; Ohashi Y; Toi M
Jpn J Clin Oncol; 2011 Jul; 41(7):867-75. PubMed ID: 21719750
[TBL] [Abstract][Full Text] [Related]
34. Elevated Levels of Serum Tumor Markers CEA and CA15-3 Are Prognostic Parameters for Different Molecular Subtypes of Breast Cancer.
Shao Y; Sun X; He Y; Liu C; Liu H
PLoS One; 2015; 10(7):e0133830. PubMed ID: 26207909
[TBL] [Abstract][Full Text] [Related]
35. Plasma DNA integrity indicates response to neoadjuvant chemotherapy in patients with locally confined breast cancer.
Lehner J; Stötzer OJ; Fersching DM; Nagel D; Holdenrieder S
Int J Clin Pharmacol Ther; 2013 Jan; 51(1):59-62. PubMed ID: 23260002
[No Abstract] [Full Text] [Related]
36. BIRC5 (survivin): a pejorative prognostic marker in stage II/III breast cancer with no response to neoadjuvant chemotherapy.
Hamy AS; Bieche I; Lehmann-Che J; Scott V; Bertheau P; Guinebretière JM; Matthieu MC; Sigal-Zafrani B; Tembo O; Marty M; Asselain B; Spyratos F; de Cremoux P
Breast Cancer Res Treat; 2016 Oct; 159(3):499-511. PubMed ID: 27592112
[TBL] [Abstract][Full Text] [Related]
37. Preoperative CA 15-3 and CEA serum levels as predictor for breast cancer outcomes.
Park BW; Oh JW; Kim JH; Park SH; Kim KS; Kim JH; Lee KS
Ann Oncol; 2008 Apr; 19(4):675-81. PubMed ID: 18037623
[TBL] [Abstract][Full Text] [Related]
38. Breast tumour volume and blood flow measured by MRI after one cycle of epirubicin and cyclophosphamide-based neoadjuvant chemotherapy as predictors of pathological response.
Stevens W; Farrow IM; Georgiou L; Hanby AM; Perren TJ; Windel LM; Wilson DJ; Sharma N; Dodwell D; Hughes TA; Dall BJ; Buckley DL
Br J Radiol; 2021 Jul; 94(1123):20201396. PubMed ID: 34106751
[TBL] [Abstract][Full Text] [Related]
39. Comparison of the efficacy and safety of the EC-T (epirubicin/cyclophosphamide followed by docetaxel) and TCb (docetaxel/carboplatin) neoadjuvant regimens in early TOP2A-normal stage II-III breast cancer.
Li WP; Zhu T; Hu MX; Yang M; Ji F; Gao HF; Yang CQ; Zhang LL; Cheng MY; Xu FP; Wang K
Neoplasma; 2020 Nov; 67(6):1409-1415. PubMed ID: 32657611
[TBL] [Abstract][Full Text] [Related]
40. Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro).
von Minckwitz G; Rezai M; Fasching PA; Huober J; Tesch H; Bauerfeind I; Hilfrich J; Eidtmann H; Gerber B; Hanusch C; Blohmer JU; Costa SD; Jackisch C; Paepke S; Schneeweiss A; Kümmel S; Denkert C; Mehta K; Loibl S; Untch M
Ann Oncol; 2014 Jan; 25(1):81-9. PubMed ID: 24273046
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
